Page last updated: 2024-12-08

androstane-3,17-dione, (5alpha)-isomer

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

androstane-3,17-dione: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

androstane-3,17-dione : An androstanoid that is androstane substituted by oxo groups at positions 3 and 17. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

5alpha-androstane-3,17-dione : The 5alpha-stereoisomer of androstane-3,17-dione. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID222865
CHEMBL ID1230438
CHEBI ID15994
SCHEMBL ID868472
MeSH IDM0309626

Synonyms (54)

Synonym
nsc 9897
einecs 212-685-5
unii-2kr72rnr8z
nsc 60796
androstanedion
5alpha-androsta-3,17-dione
2kr72rnr8z ,
dihydroandrostendione
5alpha-androstan-3,17-dione
CHEBI:15994 ,
androstane-3,17-dione, (5.alpha.)-
nsc-60796
nsc60796
5.alpha.-androstanedione
nsc9897
5.alpha.-androsta-3,17-dione
5.alpha.-androstane-3,17-dione
androstane-3, (5.alpha.)-
nsc-9897
5alpha-androstanedione
5SD ,
androstane-3,17-dione, (5alpha)-
5-alpha-androstane-3,17-dione
C00674
846-46-8
androstane-3,17-dione
androstanedione
dihydroandrostenedione
5alpha-androstane-3,17-dione
DB01561
E6DAFC26-F4E7-45D7-B0EA-D23EA6E36D0C
androstan-3,17-dione, 5alpha-
LMST02020085
10,13-dimethyl-tetradecahydro-cyclopenta[a]phenanthrene-3,17-dione
chembl1230438 ,
bdbm50025405
(5s,8r,9s,10s,13s,14s)-10,13-dimethyl-2,4,5,6,7,8,9,11,12,14,15,16-dodecahydro-1h-cyclopenta[a]phenanthrene-3,17-dione
5a-androstanedione
AKOS015955601
androstane-3,17-dione (van)
SCHEMBL868472
dihydro-androstenedione
DTXSID80233576
5a-androstane-3,17-dione
5a-andro-stanedione
W-104109
5.alpha.-androstan-3,17-dione
5a-androstane-3, 17-dione
5a-androsta-3,17-dione
androstane-3,7-dione
(5a)-androstane-3,17-dione
(5beta,8alpha,10alpha,13alpha,14beta)-androstane-3,17-dione
Q27455994
(5s,8r,10s,13s)-10,13-dimethyl-tetradecahydro-cyclopenta[a]phenanthrene-3,17-dione

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response studies revealed that the concentration of 5 alpha-androstane-3, 17-dione present in FF form normal dominant follicles (79."( A mechanism for the suppression of estrogen production in polycystic ovary syndrome.
Agarwal, SK; Judd, HL; Magoffin, DA, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
androstane-3,17-dioneAn androstanoid that is androstane substituted by oxo groups at positions 3 and 17.
3-oxo-5alpha-steroidA 3-oxo steroid that has alpha configuration at position 5.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
Androstenedione Metabolism1823
testosterone and androsterone degradation to androstendione36
superpathway of testosterone and androsterone degradation1136
Biochemical pathways: part I0466
Alternative pathway of fetal androgen synthesis717

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)0.02000.00101.979414.1600AID39178
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Olfactory receptor 51E2Homo sapiens (human)EC50 (µMol)0.00080.00000.07800.5700AID1639697
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
adenylate cyclase-activating G protein-coupled receptor signaling pathwayOlfactory receptor 51E2Homo sapiens (human)
cell migrationOlfactory receptor 51E2Homo sapiens (human)
melanocyte differentiationOlfactory receptor 51E2Homo sapiens (human)
steroid hormone mediated signaling pathwayOlfactory receptor 51E2Homo sapiens (human)
positive regulation of blood pressureOlfactory receptor 51E2Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of smellOlfactory receptor 51E2Homo sapiens (human)
cellular response to fatty acidOlfactory receptor 51E2Homo sapiens (human)
melanocyte proliferationOlfactory receptor 51E2Homo sapiens (human)
positive regulation of renin secretion into blood streamOlfactory receptor 51E2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
nuclear steroid receptor activityOlfactory receptor 51E2Homo sapiens (human)
G protein-coupled receptor activityOlfactory receptor 51E2Homo sapiens (human)
olfactory receptor activityOlfactory receptor 51E2Homo sapiens (human)
signaling receptor activityOlfactory receptor 51E2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneOlfactory receptor 51E2Homo sapiens (human)
early endosome membraneOlfactory receptor 51E2Homo sapiens (human)
intracellular organelleOlfactory receptor 51E2Homo sapiens (human)
plasma membraneOlfactory receptor 51E2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID39178In vitro antagonist activity against rat prostatic androgen receptor (AR)1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (58)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (48.28)18.7374
1990's15 (25.86)18.2507
2000's9 (15.52)29.6817
2010's6 (10.34)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.06 (24.57)
Research Supply Index4.11 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other58 (96.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]